To include your compound in the COVID-19 Resource Center, submit it here.

Bendamustine regulatory update

SymBio said South Korea approved an NDA for bendamustine to treat chronic lymphocytic leukemia (CLL) and multiple myeloma

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE